• Juan G Ripoll, Rayssa Becerra Orjuela, Anuradha Kanaparthi, Juan C Diaz Soto, Mariam A ElSaban, Thais R Peclat, Patrick M Wieruszewski, Arnoley S Abcejo, Marvin G Chang, Edward A Bittner, and Harish Ramakrishna.
• Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.
• J. Cardiothorac. Vasc. Anesth. 2024 Aug 22.

AbstractInterest in remimazolam has surged in recent years, thanks to its advantageous pharmacologic profile. This ultra-short-acting benzodiazepine is noted for its rapid onset and termination of action, organ-independent elimination, availability of a reversal agent, and excellent hemodynamic stability. Although the use of remimazolam has been explored in various anesthesia settings and procedures, data on its application in cardiovascular anesthesia and catheterization laboratory procedures remain limited. This review evaluates the latest literature to assess remimazolam's role in cardiovascular anesthesia across different settings and procedures. The analysis shows that remimazolam offers anesthesia without significant hemodynamic instability and a reduced need for vasopressors, with an incidence of perioperative adverse events comparable to that of other agents. These findings are relevant for both the induction and maintenance of general anesthesia in catheterization laboratory procedures and general anesthesia in elective cardiac surgery. Although further research is needed to fully understand remimazolam's role in cardiovascular anesthesia, its favorable hemodynamic and safety profile suggests that it is a promising option for cardiac anesthesiologists in both the catheterization laboratory and the operating room.Copyright © 2024 Elsevier Inc. All rights reserved.

4 keywords...

hide…